title: Targeting cancer with peptide aptamers.
abstract: A major endeavour in cancer chemotherapy is to develop agents that specifically target a biomolecule of interest. There are two main classes of targeting agents: small molecules and biologics. Among biologics (e.g.: antibodies), DNA, RNA but also peptide aptamers are relatively recent agents. Peptide aptamers are seldom described but represent attractive agents that can inhibit a growing panel of oncotargets including Heat Shock Proteins. Potential pitfalls and coming challenges towards successful clinical trials are presented such as optimizing the delivery of peptide aptamers thanks to Nanotechnology.
authors.affiliation: Heat Shock Proteins and Cancer, INSERM, UMR 866 IFR 100, Faculty of Medicine, 7 Boulevard Jeanne D'Arc, 21000 Dijon, France. renaud.seigneuric@u-bourgogne.fr
authors.forename: Renaud
authors.initials: R
authors.lastname: Seigneuric
authors.forename: Jessica
authors.initials: J
authors.lastname: Gobbo
authors.forename: Pierre
authors.initials: P
authors.lastname: Colas
authors.forename: Carmen
authors.initials: C
authors.lastname: Garrido
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D024221:Antineoplastic Protocols; D052158:Aptamers, Peptide / Q000737:chemistry / Q000235:genetics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006360:Heat-Shock Proteins / Q000378:metabolism; D006801:Humans; D058990:Molecular Targeted Therapy; D036103:Nanotechnology; D009369:Neoplasms / Q000188:drug therapy*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D052158:Aptamers, Peptide; D006360:Heat-Shock Proteins; D011993:Recombinant Fusion Proteins